Hester Bios

Why is Hester Biosciences Ltd falling/rising?

As of 12-Jul, Hester Biosciences Ltd's stock price is rising, currently at 2,109.40, reflecting a 0.73% increase. The stock has shown strong performance with a 32.50% year-to-date rise, significantly outperforming the Sensex, despite a recent decline in investor participation.

As of 12-Jul, Hester Biosciences Ltd's stock price is rising, currently at 2,109.40, reflecting an increase of 15.2 points or 0.73%. This upward movement is supported by the stock's performance over the last two days, where it has gained 1.17%. Additionally, the stock has outperformed its sector by 0.5% today. <BR><BR>In the broader context, Hester Biosciences has shown strong performance over the past month with a 9.04% increase, significantly outperforming the Sensex, which rose by only 4.85%. Year-to-date, the stock has increased by 32.50%, while the Sensex has declined by 8.98%. This indicates a robust growth trajectory compared to the market.<BR><BR>Despite a recent decline in investor participation, as evidenced by a 51.4% drop in delivery volume on 09 July compared to the 5-day average, the stock remains liquid enough for trading. The stock's current price is also above its 50-day, 100-day, and 200-day moving averages, which typically suggests a positive trend. <BR><BR>Overall, the combination of recent gains, strong year-to-date performance, and relative outperformance against the benchmark indicates that Hester Biosciences Ltd's stock is rising.

Which are the latest news on Hester Bios?

How big is Hester Bios?

As of 10th June, Hester Biosciences Ltd has a market capitalization of 1,658.00 Cr, with recent net sales of 332.61 Cr and net profit of 55.64 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Hester Biosciences Ltd has a market capitalization of 1,658.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 332.61 Cr, while the sum of Net Profit for the same period is 55.64 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 314.25 Cr and Total Assets valued at 653.38 Cr.

Who are in the management team of Hester Bios?

The management team of Hester Bios includes Bhupendra V Gandhi (Chairman), Rajiv D Gandhi (CEO), and several independent and non-executive directors, such as Sandhya Patel and Ameet Desai, providing a diverse governance structure.

The management team of Hester Bios includes the following individuals:<BR><BR>1. **Bhupendra V Gandhi** - Chairman & Non-Executive Director<BR>2. **Sanjiv D Gandhi** - Non-Executive & Non-Independent Director<BR>3. **Nina Gandhi** - Non-Executive Director<BR>4. **Sandhya Patel** - Independent Non-Executive Director<BR>5. **Ashok Bhadakal** - Independent Non-Executive Director<BR>6. **Ameet Desai** - Independent Non-Executive Director<BR>7. **Rajiv D Gandhi** - Executive Director, Managing Director, CEO, and Promoter<BR>8. **Ravin Gandhi** - Non-Executive & Non-Independent Director<BR>9. **Priya Rajiv Gandhi** - Executive Director<BR>10. **Anil Jain** - Independent Non-Executive Director<BR>11. **Jatin Yagneshbhai Trivedi** - Independent Non-Executive Director<BR><BR>This team brings a mix of executive and non-executive roles, contributing to the governance and strategic direction of the company.

Who are the peers of the Hester Bios?

Hester Bios' peers include Venus Remedies, Indoco Remedies, NGL Fine Chem, Windlas Biotech, Amrutanjan Health, Ind-Swift Labs, Shukra Pharma, Syncom Formulations, Beta Drugs Ltd, and Sakar Healthcare. In terms of performance, Venus Remedies leads with a 1-year return of 268.68%, while Hester Bios has a return of 6.03%.

Peers: The peers of Hester Bios are Venus Remedies, Indoco Remedies, NGL Fine Chem, Windlas Biotech, Amrutanjan Healt, Ind-Swift Labs., Shukra Pharma., Syncom Formul., Beta Drugs Ltd, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt and Shukra Pharma., while Average management risk is found at Venus Remedies, Indoco Remedies, NGL Fine Chem, Hester Bios, Windlas Biotech, Ind-Swift Labs., Syncom Formul., Beta Drugs Ltd, and Sakar Healthcare, and Below Average management risk is noted at Ind-Swift Labs. Growth is Excellent at Shukra Pharma., Good at Venus Remedies, and Below Average at Indoco Remedies, NGL Fine Chem, Hester Bios, Windlas Biotech, Amrutanjan Healt, and the rest. Capital Structure is Excellent at Venus Remedies, NGL Fine Chem, Windlas Biotech, Amrutanjan Healt, Shukra Pharma., Syncom Formul., and Beta Drugs Ltd, while Hester Bios, Indoco Remedies, Ind-Swift Labs., and Sakar Healthcare have Below Average Capital Structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Venus Remedies at 268.68%, while the peer with the lowest is Amrutanjan Healt at -19.65%. Hester Bios has a 1-year return of 6.03%, which is lower than Venus Remedies but higher than Amrutanjan Healt. Additionally, Windlas Biotech, Amrutanjan Healt, and Syncom Formul. have negative six-month returns.

What does Hester Bios do?

Hester Biosciences Ltd is an Indian animal healthcare company specializing in poultry and large animal vaccines and pet care products, with a market cap of INR 1,658 Cr and a net profit of 16 Cr for the quarter ending March 2026. The company has a P/E ratio of 31.00 and a dividend yield of 0.36%.

Overview: <BR>Hester Biosciences Ltd is a leading animal healthcare company in India, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>The company was incorporated in April 1987 and is currently engaged in manufacturing and trading poultry and large animal vaccines and pet care health products. The latest quarterly results report net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 100 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 16 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,658 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 31.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.36% <BR>Debt-Equity: 0.52 <BR>Return on Equity: 14.91% <BR>Price to Book: 4.55<BR><BR>Contact Details: <BR>Address: 1st Flr PushpakPachvati Circle, Motilal Hirabhai Road Ahmedabad Gujarat : 380006 <BR>Tel: 91-079-26445107 <BR>Email: mail@hester.in <BR>Website: http://www.hester.in

Should I buy, sell or hold Hester Biosciences Ltd?

Are Hester Biosciences Ltd latest results good or bad?

Hester Biosciences Ltd's latest Q4 FY26 results are strong, with a net profit of ₹15.98 crore and a year-on-year growth of 1,138.76%, alongside a 22.19% revenue increase. However, rising interest expenses could pose future challenges, so while the results are positive, caution is advised.

Hester Biosciences Ltd's latest results for Q4 FY26 are quite strong and indicate a significant turnaround for the company. The net profit reached ₹15.98 crore, reflecting an impressive year-on-year growth of 1,138.76%. This marks a dramatic improvement from the previous year's near-zero profitability. Revenue also saw a robust increase, totaling ₹100.11 crore, which is a 22.19% rise compared to the same quarter last year.<BR><BR>Additionally, the operating margin hit a record high of 34.29%, showcasing effective cost management and operational efficiency. This margin expansion, coupled with an 82.21% sequential increase in net profit from the previous quarter, signals strong business momentum.<BR><BR>However, it is worth noting that while the results are positive, there are concerns regarding rising interest expenses, which surged significantly in the latest quarter. This could pose challenges for future profitability if not managed carefully.<BR><BR>Overall, the latest results can be characterized as good, reflecting strong operational performance and a positive trajectory for the company, albeit with some caution regarding future interest costs.

When is the next results date for Hester Biosciences Ltd?

The next results date for Hester Biosciences Ltd is January 30, 2026.

The next results date for Hester Biosciences Ltd is scheduled for January 30, 2026.

Is Hester Bios technically bullish or bearish?

As of November 24, 2025, Hester Bios is in a strong bearish trend, indicated by bearish MACD readings, moving averages, and KST across multiple time frames, despite a mildly bullish signal from Dow Theory on the weekly chart.

As of 24 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Hester Bios is bearish with a strong indication. Key indicators driving this stance include bearish MACD readings on both weekly and monthly time frames, bearish moving averages on the daily chart, and a bearish KST on both weekly and monthly levels. The Bollinger Bands also reflect a bearish trend on the weekly chart and a mildly bearish stance on the monthly chart. Although Dow Theory shows a mildly bullish signal on the weekly, the overall bearish indicators dominate the analysis.

How has been the historical performance of Hester Bios?

Hester Bios has shown steady growth in net sales and profitability, with net sales increasing from INR 178.07 crore in March 2019 to INR 311.10 crore in March 2025, and profit after tax rising from INR 16.56 crore to INR 24.73 crore in the same period, despite some fluctuations in expenses and cash flow. Total assets and liabilities decreased slightly, while cash flow from operating activities improved significantly.

Answer:<BR>The historical performance of Hester Bios shows a steady growth in net sales and profitability over the years, with some fluctuations in specific metrics.<BR><BR>Breakdown:<BR>Hester Bios has demonstrated a consistent increase in net sales from INR 178.07 crore in March 2019 to INR 311.10 crore in March 2025. Total operating income has followed a similar trend, reaching INR 311.10 crore in March 2025, up from INR 266.09 crore in March 2023. The company's total expenditure, excluding depreciation, was INR 250.05 crore in March 2025, slightly down from INR 250.90 crore in March 2024. Operating profit (PBDIT) has shown resilience, with a figure of INR 64.97 crore in March 2025, compared to INR 64.29 crore in March 2024. Profit before tax was INR 35.47 crore in March 2025, an increase from INR 27.34 crore in March 2024, while profit after tax rose to INR 24.73 crore from INR 16.56 crore in the previous year. The company's total assets were INR 653.38 crore in March 2025, a decrease from INR 662.35 crore in March 2024, and total liabilities also decreased to INR 653.38 crore from INR 662.35 crore. Cash flow from operating activities improved significantly to INR 64.00 crore in March 2025 from INR 48.00 crore in March 2024, while net cash outflow was recorded at INR -6.00 crore in March 2025. Overall, Hester Bios has shown a positive trajectory in sales and profitability, despite some fluctuations in expenses and cash flow.

Is Hester Bios overvalued or undervalued?

As of April 1, 2025, Hester Bios is considered overvalued with a very expensive valuation grade, reflected in its high PE ratio of 57.23 and EV to EBITDA ratio of 29.14, despite a recent stock return of 15.37% that outperformed the Sensex, while its long-term performance has underperformed the index.

As of 1 April 2025, Hester Bios has moved from an expensive to a very expensive valuation grade. The company is currently considered overvalued. Key ratios include a PE ratio of 57.23, an EV to EBITDA ratio of 29.14, and a Price to Book Value of 5.01. In comparison to its peers, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Divi's Lab shows a significantly higher PE ratio of 79.33 and an EV to EBITDA of 57.35, indicating that Hester Bios is trading at a premium relative to some peers.<BR><BR>Despite a recent stock return of 15.37% over the past month, which outperformed the Sensex's 3.87%, the long-term performance shows that Hester Bios has underperformed the index year-to-date and over three years. This suggests that the current valuation may not be justified given the company's inconsistent performance relative to both its peers and the broader market.

Who are the top shareholders of the Hester Bios?

The top shareholders of Hester Bios include promoter Rajiv Dinesh Gandhi with 10.47% ownership, while public shareholder Kuntal Hasmukhlal Shah holds 3.17%. Individual investors own 32.64%, and foreign institutional investors hold 0.87%.

The top shareholders of Hester Bios include the promoters, with Rajiv Dinesh Gandhi being the promoter with the highest holding at 10.47%. The company has no pledged promoter holdings. In terms of public shareholders, Kuntal Hasmukhlal Shah holds the highest stake at 3.17%. Additionally, individual investors collectively hold 32.64% of the shares. There are also 20 foreign institutional investors (FIIs) who hold a total of 0.87%, and mutual funds are represented by two schemes, holding 0.0%.

What is the bonus history of the Hester Bios?

Hester Biosciences Ltd announced a 1:2 bonus issue on September 27, 2012, with a record date of September 29, 2012, meaning shareholders received one additional share for every two shares held.

Hester Biosciences Ltd has a bonus history that includes a 1:2 bonus issue announced on September 27, 2012. The record date for this bonus was September 29, 2012. This means that for every two shares held, shareholders received one additional share as a bonus. If you have any more questions about Hester Bios or need further details, feel free to ask!

Has Hester Bios declared dividend?

Hester Biosciences Ltd has declared a 60% dividend, amounting to ₹6 per share, with an ex-date of August 22, 2024. While the company shows mixed total returns over various periods, it has experienced significant declines in the short term but positive returns over the longer term.

Hester Biosciences Ltd has declared a 60% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 60%<BR>- Amount per share: 6<BR>- Ex-date: 22 Aug 24<BR><BR>Dividend Yield: 0.32%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -25.97%, the dividend return was 0%, resulting in a total return of -25.97%.<BR><BR>Over the past year, the price return was 4.14%, with a dividend return of 0.32%, leading to a total return of 4.46%.<BR><BR>In the 2-year period, the price return was 14.47%, the dividend return was 0.86%, culminating in a total return of 15.33%.<BR><BR>For the 3-year period, the price return was -18.58%, the dividend return was 1.15%, which resulted in a total return of -17.43%.<BR><BR>In the last 4 years, the price return was -29.74%, with a dividend return of 1.29%, leading to a total return of -28.45%.<BR><BR>Over the 5-year period, the price return was 47.13%, the dividend return was 3.36%, resulting in a total return of 50.49%.<BR><BR>Overall, Hester Biosciences Ltd has declared a significant dividend, but the total returns over various periods show mixed performance, with notable declines in the short term and positive returns over the longer term.